Evidence map›Paper›PMID 22433112›Full record

ArticleInternational journal of radiation biology2012

Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation.

Kathleen E Rodgers, Theresa Espinoza, Norma Roda, Christopher J Meeks, Colin Hill, Stan G Louie, Gere S Dizerega

Abstract read
In one paragraph

Article in International journal of radiation biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  2. Activation of Angiotensin-Converting Enzyme 2 Mitigates Gastrointestinal Acute Radiation Syndrome.International journal of radiation oncology, biology, physics · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Targets for protection and mitigation of radiation injury.Cellular and molecular life sciences : CMLS · 2020
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kathleen E RodgersSchool of Pharmacy, University of Southern California, Los Angeles, California, USA. krodgers@usc.edu
Theresa Espinoza
Norma Roda
Christopher J Meeks
Colin Hill
Stan G Louie
Gere S Dizerega
University of Southern California · US

Funding

A(1-7)-Mediated Mitigation of Radiation Induced ThrombocytopeniaRC1AI080223 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RODGERS, KATHLEEN E. · 2008 to 2010
$1.3M
NIAID NIH HHS RC1 AI080223NIAID NIH HHS RC1AI080223
6 · The paper itself

Abstract

purposeAngiotensin (1-7) [A(1-7)] is a component of the renin angiotensin system (RAS) that stimulates hematopoietic recovery after myelosuppression. In a Phase I/IIa clinical trial, thrombocytopenia after chemotherapy was reduced by A(1-7). In this study, the ability of A(1-7) to improve recovery after total body irradiation (TBI) is shown with specific attention to radiation-induced hematopoietic injury. MATERIALS AND

methodsMice were exposed to TBI (doses of 2-7 Gray [Gy]) of cesium 137 gamma rays, followed by treatment with A(1-7), typical doses were 100-1000 μg/kg given once or once daily for a specified number of days depending on the study. Animals are injected subcutaneously via the nape of the neck with 0.1 ml drug in saline. The recovery of blood and bone marrow cells was determined. Effects of TBI and A(1-7) on survival and bleeding time was also evaluated.

resultsDaily administration of A(1-7) after radiation exposure improved survival (from 60% to 92-97%) and reduced bleeding time at day 30 after TBI. Further, A(1-7) increased early mixed progenitors (3- to 5-fold), megakaryocyte (2- to 3-fold), myeloid (3- to 6-fold) and erythroid (2- to 5-fold) progenitors in the bone marrow and reduced radiation-induced thrombocytopenia (RIT) (up to 2-fold). Reduction in the number of treatments to 3 per week also improved bone marrow recovery and reduced RIT. As emergency responder and healthcare systems in case of nuclear accident or/and terrorist attack may be overwhelmed, the consequence of delayed initiation of treatment was ascertained. Treatment with A(1-7) can be delayed up to 5 days and still be effective in the reduction of RIT or acceleration of bone marrow recovery.

conclusionsThe data presented in this paper indicate that A(1-7) reduces the consequences of critical radiation exposure and can be initiated well after initial exposure with maximal effects on early responding hematopoietic progenitors when treatment is initiated 2 days after exposure and 5 days after exposure for the later responding progenitors and reduced thrombocytopenia. There was some effect of A(1-7) even when given days after radiation exposure.

Indexed as

Whole-Body IrradiationAnemiaAngiotensin IAnimalsDose-Response Relationship, DrugDose-Response Relationship, RadiationDrug Administration ScheduleFemaleHematopoiesisHematopoietic Stem CellsLeukopeniaMiceMice, Inbred C57BLPeptide FragmentsRadiation-Protective AgentsRenin-Angiotensin SystemAngiotensin Iangiotensin I (1-7)Peptide FragmentsRadiation-Protective Agents

Identifiers

PMID22433112
PMCPMC6421841
OpenAlexW2156214066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.